Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $195.28 and traded as high as $202.90. Genmab A/S shares last traded at $199.35, with a volume of 139 shares changing hands.
Genmab A/S Price Performance
The company has a 50 day simple moving average of $195.45 and a 200 day simple moving average of $205.64. The company has a market capitalization of $13.77 billion, a price-to-earnings ratio of 11.89 and a beta of 1.02.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $3.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. The business had revenue of $765.14 million during the quarter, compared to analysts' expectations of $761.09 million. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
